|Articles|January 18, 2016

Pharmacy Times

  • January 2016 The Aging Population
  • Volume 82
  • Issue 1

Rx Product News (January 2016)

Read about the new Rx Products featured in January.

GlaxoSmithKline

Indication: The FDA has approved Nucala (mepolizumab), an interleukin- 5 antagonist monoclonal antibody, for add-on maintenance treatment of patients 12 years or older with severe asthma and with an eosinophilic phenotype. The recommended dosage is 100 mg subcutaneously once every 4 weeks.

Dosage Form: Injection: 100 mg of lyophilized powder in a single-dose vial for reconstitution

For More Information: gsksource.com

Dyanavel XRMarketed by: Tris Pharma

Indication: The FDA has approved Dyanavel XR, a central nervous system stimulant, for the treatment of attention-deficit/hyperactivity disorder in children 6 years or older. The recommended starting dose is 2.5 or 5 mg once daily in the morning. The dosage may be increased in increments of 2.5 to 10 mg per day every 4 to 7 days until an optimal response is obtained.

Dosage Form: Extended-release oral suspension containing 2.5 mg of amphetamine base per mL

For More Information: trispharma.com

PraxbindMarketed by: Boehringer Ingelheim Pharmaceuticals, Inc

Indication: The FDA has approved Praxbind (idarucizumab), a humanized monoclonal antibody fragment, for patients treated with Pradaxa (dabigatran) when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/ urgent procedures or for life-threatening or uncontrolled bleeding. The recommended dose of Praxbind is 5 g, provided as 2 separate vials, each containing 2.5 g/50 mL of idarucizumab.

Dosage Form: Injection: 2.5 g/50 mL solution in a single-use vial

For More Information: boehringer-ingelheim.com

AristadaMarketed by: Alkermes

Indication: The FDA has approved Aristada (aripiprazole lauroxil) extended-release injectable suspension, an atypical antipsychotic, for the treatment of schizophrenia in adults. Aristada must be administered by intramuscular injection in the deltoid (441-mg dose only) or gluteal (441 mg, 662 mg, or 882 mg) muscle by a health care professional.

Dosage Form: Extended-release injectable suspension: 441-, 662-, or 882-mg single-use, prefilled syringe

For More Information: aristada.com

Articles in this issue

almost 10 years ago

Guidance on the Effective Use of SAMe

almost 10 years ago

Case Studies (January 2016)

almost 10 years ago

Pet Peeves (January 2016)

almost 10 years ago

Can You Read These Rxs? (January 2016)

almost 10 years ago

Drug-Induced Autoimmune Diseases

almost 10 years ago

Communicating Through Care

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


Latest CME